NCT06961448尚未招募不适用
A Prospective, Multi-center, Evaluator-blinded, Randomized, Parallel-controlled, Superiority Clinical Trial to Evaluate the Safety and Efficacy of Polycaprolactone Microsphere Fillers for Correction of Moderate to Severe Nasolabial Folds
Samyang Biopharmaceuticals Corporation0 个研究点目标入组 208 人开始时间: 2025年5月1日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 208
- 主要终点
- WSRS Responder Rate at Week 48
研究概览
简要总结
The goal of this clinical trial is to evaluate the safety and efficacy of polycaprolactone microsphere filler (Lafullen) for the correction of moderate to severe nasolabial folds in adults aged 18 and above, regardless of gender.
The main questions it aims to answer are:
- Does Lafullen improve wrinkle severity in the nasolabial fold area at 48 weeks post-injection (WSRS responder rate)?
- Is Lafullen superior to the control product (Restylane, a hyaluronic acid filler) in terms of long-term wrinkle correction and safety? Researchers will compare Lafullen (polycaprolactone filler) with Restylane (modified sodium hyaluronate gel) to see if Lafullen provides superior wrinkle correction at 12 months post-injection.
Participants will:
- Receive either Lafullen or Restylane via injection in the nasolabial fold area.
- Optionally receive a touch-up injection at 4 weeks after the first treatment if needed.
- Undergo regular follow-up visits at 4, 12, 24, 36, and 48 weeks post-treatment.
- Subjects in the Lafullen group will continue follow-up up to 72 weeks to assess long-term efficacy and safety.
- Be assessed through clinical photography, pain scale (VAS), satisfaction questionnaires, and safety evaluations (e.g., AEs, vital signs, lab tests).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 or above, with no gender restriction.
- •Willing to receive treatment for correcting nasolabial fold.
- •Treatment investigator evaluate those with a WSRS score of 3 or 4 for bilateral nasolabial folds;
- •Willing to voluntarily participate in the clinical trial, accepting the obligation not toreceive all plastic surgery and cosmetic dermatology procedures or treatments during the trial。 Willing and able to undergo the required treatment and follow-up observations, and sign the informed consent form.
排除标准
- •Allergy to polycaprolactone, hyaluronic acid products or any component of the investigational device or control device(such as streptococcal proteins), allergy to any local anesthetic (such as lidocaine or other amide-typeanesthetic), or history of severe allergic reactions and multiple severe allergic reactions.
- •Previous surgery, cosmetic facial procedure, or plans to undergo cosmetic surgery in NLF area or lower face during the trial, inculding any of the following circumstances:
- •Received permanent fillers or prostheses (such as PMMA etc.) or semi-permanent dermal fillers (such as CaHA, PLLA, PCL, etc.).
- •Received temporary dermal fillers (such as HA and collagen etc.) within 12 months prior to screening.
- •Received anti-wrinkle surgery within 12 months prior to screening.
- •Receiving botulinum toxin injection, chemical stripping, radiofrequency laser, and liquid nitrogen freezing anti-wrinkle treatment within 6 months.
- •Individuals who used topical agents (e.g., corticosteroids, steroids [excluding hydrocortisone], retinoids, or retinoid derivatives intended as medications but not as cosmetics) on the mid-to-lower facial area within 3 months prior to screening or plan to use them during the trial period, as well as those undergoing hydrocortisone treatment.
- •Individuals with abnormal coagulation mechanisms [activated partial thromboplastin time (APTT) >1.5 times the upper limit of normal (ULN), etc.], or use of anticoagulants (e.g., warfarin, rivaroxaban), antiplatelet agents (e.g., aspirin, clopidogrel), thrombolytic agents (e.g., recombinant human urokinase) within 2 weeks prior to screening.
- •Individuals with severe liver or kidney dysfunction, such as liver function markers (ALT, AST) exceeding 2 times the ULN or kidney function markers (creatinine) exceeding 1.5 times the ULN.
- •Individuals with infectious diseases, including any positive test results for hepatitis B surface antigen, hepatitis C antibodies, HIV antibodies, or syphilis antibodies.
- •Individuals with scars, unhealed wounds, deformities, defects, tattoos, or excessive pigmentation in the nasolabial fold area that may affect the efficacy assessment.
- •Individuals with tumors, precancerous lesions, active skin lesions such as herpes, in the nasolabial fold area.
- •Individuals with acute or chronic skin diseases such as infections or inflammation in the treatment area.
- •Individuals with autoimmune diseases, such as psoriasis.
- •Individuals with uncontrolled diabetets.
- •Individuals prone to scarring, keloid formation, or hypertrophic scars.
- •Individuals diagnosed with psychiatric disorders, lacking self-autonomy, or experiencing active episodes of anxiety or depression.
- •Individuals with excessively high expectations of treatment outcomes or unwilling to accept potential short-term side effects such as bruising, swelling, or pain.
- •Individuals who are pregnant, breastfeeding, or unwilling to use medically approved contraception (e.g., oral contraceptives, condoms, intrauterine devices) during the trial.
- •Individuals who participated in other drug or medical device clinical trials within 3 months prior to screening.
- •Individuals deemed unsuitable for trial participation by the investigator for other reasons.
结局指标
主要结局
WSRS Responder Rate at Week 48
时间窗: 48 weeks after injection
Wrinkle Severity Rating Scale (WSRS) responder rate: Percentage of participants showing ≥1-point improvement from baseline in WSRS on both sides of the nasolabial folds, as evaluated by a blinded assessor using standardized facial photographs. A higher percentage indicates greater wrinkle correction efficacy.
次要结局
未报告次要终点
研究者
相似试验
Enrolling By Invitation
2 期
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）NCT06910072Cancer Institute and Hospital, Chinese Academy of Medical Sciences32
已完成
2 期
Intravenous Administration of Microplasmin for Treatment of Acute Ischemic StrokeStroke, AcuteNCT00123305ThromboGenics40
已完成
不适用
Effectiveness of Paclitaxel-coated Luminor® Balloon Catheter Versus Uncoated Balloon Catheter in the Arteria Femoralis SuperficialisPeripheral Arterial DiseaseNCT02540018Jena University Hospital172
已完成
不适用
Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent RestenosisCoronary RestenosisNCT02944890ZhuHai Cardionovum Medical Device Co., Ltd.242
已完成
3 期
Pioglitazone Add-on Study in Patients With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT00086502Merck Sharp & Dohme LLC353